A transplant crossmatch is a compatibility assessment used in organ transplantation to determine whether a recipient has pre-existing antibodies that react with a particular donor. A laboratory, or physical, crossmatch tests recipient serum against donor cells; a virtual crossmatch compares the recipient’s antibody profile with the donor’s tissue-typing results. Crossmatching helps assess the risk of antibody-mediated transplant rejection, especially in kidney transplantation. It is distinct from blood-group compatibility testing and does not establish that a transplant will be free of rejection.
Immunological basis
The principal targets assessed in routine transplant crossmatching are human leukocyte antigens (HLA), cell-surface proteins involved in immune recognition. HLA molecules vary considerably between individuals. A recipient may develop antibodies against non-self HLA through previous transplantation, blood transfusion, or pregnancy—exposures collectively described as sensitizing events.
Antibodies directed against HLA carried by a particular donor are called donor-specific antibodies (DSA). If present before transplantation, some can bind to the graft’s blood-vessel lining and activate the complement system or other immune mechanisms. This can cause rapid vascular injury, including hyperacute rejection, or contribute to subsequent antibody-mediated rejection.
HLA matching and crossmatching answer different questions. HLA matching describes similarities and differences between donor and recipient HLA types; crossmatching assesses whether the recipient already has antibodies capable of reacting with that donor. A substantial HLA mismatch does not necessarily produce a positive crossmatch.
Main methods
Complement-dependent cytotoxicity crossmatch
The complement-dependent cytotoxicity crossmatch (CDC crossmatch) incubates donor lymphocytes with recipient serum and then adds complement. If recipient antibodies bind to the donor cells and activate complement sufficiently, the cells are damaged or killed. Cell viability is assessed using indicator dyes.
The assay detects antibodies capable of producing complement-mediated cell injury under the test conditions. Antihuman-globulin enhancement can increase its sensitivity.
A positive result attributable to donor-specific HLA antibodies, particularly on donor T cells, has historically been associated with a substantial risk of hyperacute rejection in kidney transplantation. However, CDC positivity can also reflect other reactivity, including some IgM antibodies or autoantibodies. Additional testing may therefore be needed to establish its significance.
Flow-cytometric crossmatch
A flow-cytometric crossmatch measures antibody binding to donor lymphocytes using fluorescently labelled detection antibodies and flow cytometry. It is generally more sensitive than conventional CDC testing and can detect antibody binding even when the antibodies do not produce measurable complement-dependent cell death.
Results are commonly reported separately for:
- T cells, which generally express HLA class I.
- B cells, which express HLA class I and class II.
T-cell reactivity can indicate antibodies against class I HLA. B-cell reactivity may reflect antibodies against class I, class II, or other targets. Neither pattern identifies antibody specificity by itself.
Results depend on validated laboratory thresholds and testing procedures. Nonspecific binding, donor-cell preparation, and certain therapeutic antibodies can complicate interpretation.
Virtual crossmatch
A virtual crossmatch predicts donor–recipient compatibility without directly mixing recipient serum with donor cells. It combines the donor’s HLA type with the recipient’s known HLA antibody specificities, usually characterized by solid-phase assays such as single-antigen bead testing.
Virtual crossmatching can support rapid organ allocation and reduce delays associated with transporting donor cells or performing physical testing. Its reliability depends on sufficiently complete donor typing, appropriate antibody testing, and serum samples that reflect the recipient’s current sensitization status.
A virtual crossmatch is not a direct measurement of antibody binding to donor cells. Antibody assays may show reactivity to altered antigens on test beads, miss some relevant antibodies, or yield results affected by assay interference. Whether a physical crossmatch is also performed depends on the organ, laboratory protocol, and clinical circumstances.
Interpreting results
A negative crossmatch means that the method did not detect donor-reactive antibodies above its defined threshold. It lowers concern about certain forms of pre-existing antibody-mediated incompatibility but does not exclude all donor-specific antibodies or all mechanisms of rejection.
A positive crossmatch indicates donor-cell reactivity in a physical assay, or predicted incompatibility in a virtual assessment. Its significance depends on:
- The method used and strength of reactivity.
- Whether T cells, B cells, or both are reactive.
- Whether donor-specific HLA antibodies explain the result.
- Current and historical antibody findings.
- Recent sensitizing events and treatments that may interfere with testing.
- The organ being transplanted.
Results from different methods can disagree because they measure different properties: cell killing, antibody binding, or predicted antigen recognition. A flow-positive but CDC-negative result, for example, does not carry the same meaning as a strongly positive CDC crossmatch.
Single-antigen bead assays commonly report mean fluorescence intensity. This is a semiquantitative assay signal, not a universal antibody concentration or a directly interchangeable measure of transplant risk. There is no single threshold that defines clinically important incompatibility across all laboratories.
Clinical uses and boundaries
Crossmatching is especially established in transplantation of the kidney. Identifying donor-specific incompatibility can influence donor selection, organ allocation, and the use of kidney paired donation. Some specialized programs undertake transplantation across selected antibody incompatibilities using defined protocols; such procedures do not make a positive crossmatch equivalent to a negative one.
Crossmatch practices differ among kidney, heart, lung, liver, and other organ transplantation because antibody-associated risks and the time available for testing differ. In hematopoietic stem cell transplantation, donor-specific HLA antibodies can also be relevant to graft failure, particularly with HLA-mismatched donors, although assessment pathways differ from those used for solid organs.
Crossmatching does not replace blood-group assessment, infectious-disease testing, donor evaluation, or immunosuppressive treatment. It primarily assesses pre-existing antibody-related risk, not all cellular immune responses or antibodies that may develop after transplantation. Antibody profiles can also change over time, so a result describes compatibility under the conditions and at the time assessed rather than a permanent property of a donor–recipient pair.